In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors

2015 ◽  
Vol 29 (6) ◽  
pp. 604-614 ◽  
Author(s):  
Edouard Ollier ◽  
Sophie Hodin ◽  
Thierry Basset ◽  
Sandrine Accassat ◽  
Laurent Bertoletti ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vivo Evaluation ◽  
Drug Drug Interaction

In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine

1999 ◽  
Vol 145 (1) ◽  
pp. 91-98 ◽  
Author(s):  
W.-H. Chang ◽  
Bruce Augustin ◽  
Hsien-Yuan Lane ◽  
Troy ZumBrunnen ◽  
Hui-Ching Liu ◽  
...  
Keyword(s):  
Drug Interaction ◽  
In Vivo Evaluation ◽  
Drug Drug Interaction

In vitro and in vivo Drug-Drug Interaction of Losartan and Glimepiride in Rats and Its Possible Mechanism

Pharmacology ◽  
2015 ◽  
Vol 95 (3-4) ◽  
pp. 133-138 ◽  
Author(s):  
Sai-Zhen Chen ◽  
Pei-Pei Pan ◽  
Shuang-Hu Wang ◽  
Jun Luo ◽  
Guo-Xin Hu ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Drug Drug Interaction

The potential drug-drug interaction between proton pump inhibitors and warfarin

2015 ◽  
Vol 24 (12) ◽  
pp. 1337-1340 ◽  
Author(s):  
Daniel Pilsgaard Henriksen ◽  
Tore Bjerregaard Stage ◽  
Morten Rix Hansen ◽  
Lotte Rasmussen ◽  
Per Damkier ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Potential Drug ◽  
Drug Drug Interaction

Results from Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications

2020 ◽  
Vol 45 (4) ◽  
pp. 433-444
Author(s):  
Roland Heinig ◽  
Michael Gerisch ◽  
Michaela Bairlein ◽  
Johannes Nagelschmitz ◽  
Stephanie Loewen
Keyword(s):  
Drug Interaction ◽  
Interaction Studies ◽  
Drug Drug Interaction

scholarly journals The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo

2018 ◽  
Vol 108 ◽  
pp. 60-64 ◽  
Author(s):  
Miao Yan ◽  
Zhu-feng Wu ◽  
Dan Tang ◽  
Feng Wang ◽  
Yi-wen Xiao ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
The Impact

Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study

2013 ◽  
Vol 28 (11) ◽  
pp. 1475-1479 ◽  
Author(s):  
J.M. Shin ◽  
J.Y. Lee ◽  
D.Y. Lee ◽  
T.Y. Yoon ◽  
J.C. Lee ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vitro Study ◽  
Vitro Study ◽  
Possible Cause

The deleterious association between proton pump inhibitors and prostate cancer specific death.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 309-309
Author(s):  
Hanan Goldberg ◽  
Faizan Moshin ◽  
Refik Saskin ◽  
Girish S. Kulkarni ◽  
Alejandro Berlin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cox Regression ◽  
Population Based ◽  
Study Data ◽  
History Of ◽  
Time Dependent Covariates

309 Background: Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Although in-vitro and in-vivo data have shown PPIs to have anti-tumor effects, more recent studies suggest an increased cancer risk in several solid organs. Pantoprazole, a commonly prescribed PPI, has been shown to harbor a protective effect in human prostate cancer (PCa) cells. We aimed to investigate the effect of pantoprazole and other PPIs on PCa-specific death and additional PCa outcomes. Methods: In this retrospective, population-based cohort study, data were incorporated from the Institute for Clinical and Evaluative Sciences to identify all men aged 66 and above with a history of a single negative prostate biopsy between 1994 and 2016. We used multivariable Cox regression models with time-dependent covariates, to assess the effect of PPIs on PCa diagnosis, androgen deprivation therapy (ADT) use, and PCa-specific death. All models included other medications with a putative effect on PCa. All models were adjusted for age, rurality, comorbidity, and year of patient study inclusion. Results: Overall, 21,512 men were included, with a mean follow-up time of 8.06 years (SD 5.44 years). A total of 10,999 patients (51.1%) used a PPI. A total of 5,187 patients (24.1%) were diagnosed with PCa, 2,043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. Pantoprazole was associated with a 3.0% (95% CI 0.3%-6,0%) increased rate of being treated with ADT for every six months of cumulative use, while any use of all other PPIs was associated with a 39.0% (95% CI 18.0%-64.0%) increased PCa-specific mortality. No significant association was found with PCa diagnosis. Conclusions: Upon validation of the potentially negative association of PPIs with PCa outcomes, the expansive use of PPIs may need to be reassessed, especially in PCa patients.

Sign in / Sign up

Export Citation Format

Share Document